Selective Antitumor Therapy Based on Nanotechnology

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 2253

Special Issue Editors


E-Mail Website
Guest Editor
GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Interests: nanotechnology; bioconjugation; multifuntionalization; polymeric nanoparticles; drug delivery; nanotheranostic
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
GENYO Researcher Centre, University of Granada, Granada, Spain
Interests: nanomedicine; bioconjugation; preclinical characterization

Special Issue Information

Dear Colleagues,

In recent years, nanotechnology has been widely implemented in cancer treatment due to the importance of nanoparticles as drug delivery systems. The continuous development in this area provides alternative approaches to overcome the limitations of conventional cancer therapy. Drug targeting by using functionalized nanoparticles that improve their pharmacokinetic properties was one of the first milestones to be achieved, obtaining highly specific, non-toxic and biocompatible nanoformulations. The current trend is towards personalized medicine through a paradigm shift in the orientation towards new targets, such as cellular organelles that increase drug efficacy. One of the current key challenges is the design of nanodevices that avoid cellular drug resistance mechanisms and improve the penetration of solid tumors. On the other hand, immunotherapy offers new opportunities for nanomedicine to label tumor cells for recognition by the immune system. Advanced tissue models that reflect tumor heterogeneity are being developed to establish safe and effective nanoformulations.  Additionally, a current challenge is to deepen the mechanisms of action of the developed nanosystems.

This Special Issue aims is to publish original research articles and reviews focusing on the latest developments in nanotechnology-based targeted antitumor therapy. This Special Issue welcomes research findings that help to improve cancer therapy by applying strategies based on nanoparticles, such as polymeric nanoparticles, inorganic nanoparticles, liposomes, dendrimers, exosomes, etc.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: targeted drug delivery, theranostics, DNA nanotechnology, nanovectors, gene delivery, gene editing, strategies to overcome drug resistance, immunotherapy, tumor models to validate nanoformulations, the mechanisms of action of nanodevices, nanotoxicology, the preclinical characterization of nanodevices, bio-inspired nanomaterials, exosomes for cancer therapy, etc.  

We look forward to receiving your contributions.

Dr. Rosario M. Sanchez-Martin
Dr. Victoria Cano-Cortés
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • drug delivery
  • nucleic acid delivery
  • cancer
  • nanomedicine
  • targeted therapy
  • drug resistance
  • bio-inspired nanomaterials

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 3065 KiB  
Review
pH-Sensitive Targeting of Tumors with Chemotherapy-Laden Nanoparticles: Progress and Challenges
by Zuha Imtiyaz, Jiaxi He, Qixin Leng, Atul K. Agrawal and A. James Mixson
Pharmaceutics 2022, 14(11), 2427; https://doi.org/10.3390/pharmaceutics14112427 - 10 Nov 2022
Cited by 4 | Viewed by 1851
Abstract
Accumulating chemotherapeutic drugs such as doxorubicin within a tumor while limiting the drug dose to normal tissues is a central goal of drug delivery with nanoparticles. Liposomal products such as Doxil® represent one of the marked successes of nanoparticle-based strategies. To replicate [...] Read more.
Accumulating chemotherapeutic drugs such as doxorubicin within a tumor while limiting the drug dose to normal tissues is a central goal of drug delivery with nanoparticles. Liposomal products such as Doxil® represent one of the marked successes of nanoparticle-based strategies. To replicate this success for cancer treatment, many approaches with nanoparticles are being explored in order to direct and release chemotherapeutic agents to achieve higher accumulation in tumors. A promising approach has been stimulus-based therapy, such as the release of chemotherapeutic agents from the nanoparticles in the acidic environments of the tumor matrix or the tumor endosomes. Upon reaching the acidic environments of the tumor, the particles, which are made up of pH-dependent polymers, become charged and release the entrapped chemotherapy agents. This review discusses recent advances in and prospects for pH-dependent histidine-based nanoparticles that deliver chemotherapeutic agents to tumors. The strategies used by investigators include an array of histidine-containing peptides and polymers which form micelles, mixed micelles, nanovesicles, polyplexes, and coat particles. To date, several promising histidine-based nanoparticles have been demonstrated to produce marked inhibition of tumor growth, but challenges remain for successful outcomes in clinical trials. The lessons learned from these histidine-containing particles will provide insight in the development of improved pH-dependent polymeric delivery systems for chemotherapy. Full article
(This article belongs to the Special Issue Selective Antitumor Therapy Based on Nanotechnology)
Show Figures

Graphical abstract

Back to TopTop